Last reviewed · How we verify
Familial hypercholesterolemia - heterozygous
Approved treatments
- Niaspan · Medpointe Pharm Hlc
- Ezetrol · NVP Healthcare
- Niaspan · Cedars-Sinai Medical Center
- Lescol · Novartis
Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol. - Praluent · Sanofi
Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels. - Leqvio · Novartis
Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors. - Zetia · Merck & Co.
Zetia works by blocking the absorption of cholesterol in the small intestine. - Lipitor · Pfizer Inc.
Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. - Zocor · Merck & Co.
- Praluent · Regeneron Pharmaceuticals
- Nicotinic Acid · MEDPOINTE PHARM HLC
- Tricor (Micronized) · Salix
Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion. - Crestor · AstraZeneca
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor. - Nexletol · Esperion Theraps Inc
NEXLIZET reduces LDL-C by inhibiting cholesterol synthesis in the liver and absorption in the intestine. - Lipitor · Pfizer
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis. - Repatha · Repatha
Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL. - Trilipix · AbbVie
- Mevacor · Merck & Co.
Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver.
Clinical guidelines
- FDA label — adj
As an adjunct to diet to reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Familial hypercholesterolemia - heterozygous patent landscape — cliff calendar, originator estates, attackable patents
- Familial hypercholesterolemia - heterozygous treatment landscape brief
- Familial hypercholesterolemia - heterozygous treatment updates RSS
Frequently asked questions about Familial hypercholesterolemia - heterozygous
What drugs treat Familial hypercholesterolemia - heterozygous?
Tracked treatments include Niaspan, Ezetrol, Lescol, Praluent, Leqvio, Zetia, Lipitor, Zocor.
What is the treatment for Familial hypercholesterolemia - heterozygous?
Standard treatment for Familial hypercholesterolemia - heterozygous includes Niaspan, Ezetrol, Lescol, Praluent, Leqvio. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Familial hypercholesterolemia - heterozygous?
FDA label publishes guidelines for Familial hypercholesterolemia - heterozygous. 1 guideline references tracked.
Related
- Treatment landscape: Familial hypercholesterolemia - heterozygous patent cliff · Familial hypercholesterolemia - heterozygous CI report
- Treatment: Niaspan · Medpointe Pharm Hlc
- Treatment: Ezetrol · NVP Healthcare
- Treatment: Niaspan · Cedars-Sinai Medical Center
- Treatment: Lescol · Novartis
- Treatment: Praluent · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing